000 03710nam a22004455c 4500
999 _c6902
_d6902
001 6902
003 ES-MaUEC
005 20200701131632.0
006 a||||fo|||| 00| 0
007 cr nn 008mamaa
008 181214s2019 gw a s |||| 0|eng d
020 _a9783319438962
024 7 _a10.1007/978-3-319-43896-2
_2doi
040 _bspa
_cES-MaUEC
_dES-MaUEC
050 4 _aRM301.15
_b.C36 2019EB
245 0 0 _aCancer Policy: Pharmaceutical Safety
_cedited by June M. McKoy, Dennis P. West.
264 1 _aCham
_bSpringer International Publishing :
_bImprint: Springer
_c2019.
300 _aV, 128 páginas 1 ilustraciones
336 _2rdacontent
_aTexto (visual)
_btxt
337 _2rdamedia
_aelectrónico
_bc
338 _2rdacarrier
_arecurso electrónico
_bcr
347 _atext file
_bPDF
_2rda
490 1 _aCancer Treatment and Research,
_x0927-3042 ;
_v171
490 0 _aMedicine (Springer-11650)
505 0 _aPharmacovigilance programs: Do they improve Cancer Drug Safety? -- Impact of Cost on the Safety of Cancer pharmaceuticals -- Assessing pharmaceutical safety in Geriatric Oncology -- Cancer co-Morbidity: Implications for Drug Safety -- Statistical aids to signal generation: Are they effective in Identifying Adverse Cancer Drug Reactions? -- Pharmacovigilance of alternative medications in the Cancer Setting -- Key elements in Adverse Drug Interaction Safety Signals: evaluation of individual case reports in oncology -- Biosimilars: Are they really safe? -- Natural Language processing: improving the identification and communication of Cancer Drug Safety -- The Drug Shortage Crisis in the United States: Impact on cancer pharmaceutical safety -- Anatomy of Risk Evaluation and Mitigation Strategies (REMS) -- Cancer Drug Toxicity: Moving from patient to Survivor.
520 3 _aCancer Policy: Pharmaceutical Safety provides invaluable information on the interesting and compelling field of cancer drug safety. Identifying and understanding high-priority policy issues and key pharmacovigilance strategies is of paramount importance. In this volume, outstanding and original chapters provide an overview and synthesis of the latest thoughts and findings relating to drug safety in the cancer domain. Topics include natural language processing and pharmacovigilance of alternative cancer pharmaceuticals. The information presented in this volume will improve understanding of emerging strategies to identify adverse drug reactions and drug-drug interactions within the cancer setting and will highlight policies that have been instituted to improve cancer patient safety. In summary, Cancer Policy: Pharmaceutical Safety explores many of the important areas of pharmacovigilance research in oncology.
988 _aPrimersemestre_2019_Medicine
650 1 4 _aOncology.
_0http://scigraph.springernature.com/things/product-market-codes/H33160
650 2 4 _aDrug Safety and Pharmacovigilance.
_0http://scigraph.springernature.com/things/product-market-codes/H69010
_9549428
653 0 _aOncology  .
700 1 _aMcKoy, June M.
_eeditor literario
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
700 1 _aWest, Dennis P.
_eeditor literario
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
710 2 _aSpringerLink (Online service)
_9106937
776 0 8 _iPrinted edition:
_z9783319438948
776 0 8 _iPrinted edition:
_z9783319438955
830 0 _aCancer Treatment and Research,
_x0927-3042 ;
_v171
856 4 0 _uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-319-43896-2
_zAcceso a este recurso digital (usuarios Universidad Europea de Valencia)
942 _2lcc
_cLE
998 _db
_feng
_ggw
_h0
_el